AxoGen Inc (AXGN) shares surged 6.33% on Tuesday, February 25th, 2025, following the company's better-than-expected fourth-quarter 2024 earnings and revenue results and upbeat 2025 guidance.
The regenerative medicine company reported adjusted earnings per share of $0.07 for the fourth quarter, surpassing analysts' expectations of $0.03. Revenue grew 15.1% year-over-year to $49.41 million, exceeding the consensus estimate of $48.57 million. The strong performance was attributed to improved commercial execution and growing adoption of its products.
Furthermore, AxoGen provided an optimistic outlook for 2025, projecting revenue growth of 15% to 17% and gross margin in the range of 73% to 75%. The company also expects to be net cash flow positive for the full year, driven by its strategic initiatives and growth plans.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.